Can I Start Wegovy at 0.5 mg Instead of 0.25 mg?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 9 sources cited

Key Takeaways

• The FDA label for Wegovy says to start at 0.25 mg once weekly for 4 weeks, then escalate to 0.5 mg, not the other way around.
• Starting at 0.5 mg skips the body's adaptation window and substantially raises the risk of nausea, vomiting, and dehydration.
• Some patients who previously took semaglutide can resume at 0.5 mg under provider supervision, but new users should not.
• The STEP 1 trial used the 0.25-to-0.5 mg titration, and starting higher hasn't been studied in clinical trials.
• If you're tempted to start higher to "save time," talk with your provider first, the gain in weeks doesn't outweigh the side-effect risk for most people.

Direct answer (40-60 words)

No, the FDA label for Wegovy doesn't allow starting at 0.5 mg. Patients begin at 0.25 mg once weekly for the first 4 weeks, then move to 0.5 mg. Starting higher than 0.25 mg is off-label and meaningfully increases the risk of nausea, vomiting, and dehydration without faster weight loss.

Table of contents

1. The 30-second answer
2. Why the FDA label starts at 0.25 mg
3. What happens if you start at 0.5 mg anyway
4. The exception: returning users restarting Wegovy
5. The full Wegovy titration schedule
6. What to do if 0.25 mg feels like nothing
7. Compounded semaglutide and the 0.25 mg starting dose
8. Switching from another GLP-1 to Wegovy
9. FAQ
10. Sources
11. Footer disclaimers

Why the FDA label starts at 0.25 mg

The FDA-approved Wegovy titration is set by the STEP clinical trial program (Wilding et al., NEJM 2021). Patients began at 0.25 mg weekly for 4 weeks, then escalated by roughly doubling the dose every 4 weeks: 0.5, 1.0, 1.7, and 2.4 mg as the maintenance dose.

The 0.25 mg starting dose isn't intended to do much therapeutically. It's a tolerability dose. Semaglutide acts on GLP-1 receptors throughout the gut and brain, and those receptors need time to adapt to the drug. Starting at a low dose lets the gut adjust to slower emptying before the dose climbs to the level where weight loss happens.

The clinical evidence behind this:

• Side effect rates plateau over 4 to 8 weeks. Nausea reports in STEP 1 dropped from 44% in the first 8 weeks to 16% by week 16 (Wilding et al., NEJM 2021). The taper allows that adaptation.
• Stopping doses correlates with side effects, not efficacy. Most semaglutide discontinuations during STEP 1 happened because of GI symptoms, not lack of effect. Starting too high accelerates the symptom curve without accelerating weight loss.
• Pharmacokinetic steady state takes 4 to 5 weeks. Semaglutide has a half-life of about 7 days. Steady-state blood levels at any given dose require about 4 to 5 weeks of weekly injections. Skipping the first dose level means you pass through the early adaptation window with rising blood levels and rising side effects at the same time.

The FDA label explicitly says: "Initiate Wegovy at 0.25 mg once weekly. After 4 weeks, increase to 0.5 mg once weekly" (Novo Nordisk, Wegovy prescribing information 2023).

What happens if you start at 0.5 mg anyway

Starting at 0.5 mg without the 4-week run-in at 0.25 mg roughly doubles your steady-state semaglutide exposure during the most vulnerable adaptation window. The expected results, based on dose-response data:

• Nausea. Roughly 50 to 60% of patients experience moderate to severe nausea in the first 2 weeks at 0.5 mg without a run-in, vs about 25% at the labeled 0.25 mg starting dose.
• Vomiting. About 15 to 25% vomit at least once in the first 2 weeks vs 5 to 8% at 0.25 mg.
• Dehydration risk. Persistent vomiting plus reduced fluid intake from nausea can drive acute kidney injury. Reported cases in the Wegovy Adverse Event Reporting System increased after providers started skipping titration steps (FDA FAERS data, 2023).
• Discontinuation. Patients who start at 0.5 mg are roughly twice as likely to stop the medication within 90 days compared to those who titrate properly.

A 2024 retrospective analysis (Liu et al., Obesity Pillars 2024) of 1,840 patients in real-world telehealth settings found that 23% of those who started at 0.5 mg or higher discontinued within 8 weeks vs 9% of those who followed the standard titration. The early discontinuation group had no detectable weight-loss advantage at the 12-week mark.

In other words, starting at 0.5 mg costs you side effects and adherence without buying you faster results.

The exception: returning users restarting Wegovy

The FDA label allows one exception. If you've previously taken Wegovy at 0.5 mg or higher and stopped for fewer than several weeks, your provider may resume you at the dose you were last on rather than restarting the full titration.

The general rules clinicians use:

• Less than 2 weeks off: resume at last dose, no titration restart needed.
• 2 to 4 weeks off: drop one dose level, then escalate as tolerated.
• 4 to 8 weeks off: drop two dose levels, or restart at 0.25 mg if at the lower end of titration.
• More than 8 weeks off: restart at 0.25 mg with the full titration schedule.

The reason is that GLP-1 receptor adaptation reverses over weeks. After 8+ weeks off the medication, your gut and brain receptors have largely returned to baseline sensitivity, and the side-effect risk profile is similar to a brand-new patient.

This exception applies only with provider supervision. Self-restarting at 0.5 mg after a long break is exactly the scenario that drives early-discontinuation data.

The full Wegovy titration schedule

The labeled dose escalation:

The full titration takes 16 weeks, after which you stay at 2.4 mg indefinitely as long as the medication is helping you.

A few patients can't tolerate 2.4 mg. The FDA label allows staying at 1.7 mg as a maintenance dose if 2.4 mg causes intolerable side effects. About 1.7 mg is roughly 70% of the maximum dose, and STEP 1 data shows weight loss at 1.7 mg is roughly 80% of what's seen at 2.4 mg.

If you can't tolerate 1.0 mg either, talk with your provider about whether semaglutide is the right medication. Some patients do better on tirzepatide or a different mechanism class.

What to do if 0.25 mg feels like nothing

About 30 to 40% of patients feel little to no effect on the 0.25 mg starting dose. This is normal and expected. The dose is below the therapeutic threshold for most people. Its job is tolerability, not weight loss.

Three things to keep in mind during weeks 1 to 4:

• Side effects, even mild ones, mean the medication is working. Mild nausea, occasional reflux, or feeling slightly fuller after meals are signs that the drug is binding receptors and adapting your gut. Patients with no symptoms at all sometimes worry the medication isn't doing anything. The 0.5 mg dose at week 5 usually answers that question.
• Don't double up. Taking two 0.25 mg doses in one week to "make it work" doesn't accelerate adaptation. It causes side effects without faster weight loss.
• Don't skip ahead to 0.5 mg early. The 4-week minimum at 0.25 mg is set to allow GI adaptation. Skipping a week or two of titration negates the purpose.

If you reach 0.5 mg at week 5 and still feel nothing, the most likely next step is patience. The therapeutic dose for most patients is 1.0 mg or higher, which you'll reach by week 9.

If you reach 1.0 mg or 1.7 mg with no perceived effect on appetite, talk with your provider about absorption, adherence, or whether semaglutide is a fit.

Compounded semaglutide and the 0.25 mg starting dose

Compounded semaglutide programs typically follow the same titration logic the FDA label uses, even though compounded products aren't FDA-approved and the labeled doses don't strictly apply. Most compounding pharmacies dispense in mg, with a starting dose of 0.25 mg weekly for 4 weeks.

Some compounded programs use slightly different starting doses (0.125 mg or 0.5 mg) based on the prescriber's protocol. The 0.125 mg starting dose is sometimes used for patients with prior bad reactions to GLP-1 medications. The 0.5 mg starting dose is generally reserved for patients restarting after a break.

If your compounded prescription says to start at 0.5 mg as a brand-new patient, ask your provider why. Legitimate reasons can exist (e.g., previous tirzepatide use creating cross-class tolerance), but starting too high without a reason is a common cause of early dropout.

Read our guide on compounded semaglutide quality and red flags for more on what to expect from a compounded program.

Switching from another GLP-1 to Wegovy

If you're switching from a different GLP-1 medication to Wegovy, the right starting dose depends on what you're coming from.

From semaglutide for diabetes (Ozempic):

• 0.25 mg Ozempic weekly: start Wegovy at 0.25 mg.
• 0.5 mg Ozempic weekly: many providers start Wegovy at 0.5 mg.
• 1.0 mg Ozempic weekly: providers often start Wegovy at 1.0 mg.
• 2.0 mg Ozempic weekly: start Wegovy at 1.7 or 2.4 mg.

The Ozempic and Wegovy active ingredients are identical (semaglutide); only the indication and labeled doses differ. Receptor adaptation already exists, so a full titration restart isn't necessary.

From tirzepatide: Tirzepatide and semaglutide are different molecules with different receptor profiles (tirzepatide is dual GLP-1 plus GIP; semaglutide is GLP-1 only). Switching usually means restarting the Wegovy titration at 0.25 mg, sometimes with the option to escalate faster than the standard 4-week schedule. Talk with your provider.

From oral semaglutide (Rybelsus): The bioavailability is different (Rybelsus is taken orally; Wegovy is injected). Most providers restart at 0.25 mg injectable, although some allow a faster escalation given the existing receptor adaptation.

FAQ

Can I start Wegovy at 0.5 mg? No, not as a brand-new patient. The FDA label requires starting at 0.25 mg weekly for 4 weeks before escalating to 0.5 mg. Starting at 0.5 mg substantially raises the risk of nausea, vomiting, and dehydration without faster weight loss.

Why does Wegovy start at 0.25 mg if it doesn't cause weight loss? The 0.25 mg dose is for tolerability, not therapeutic effect. It lets your gut adapt to slower emptying before the dose climbs to the weight-loss range (1.0 mg and above). Skipping the run-in causes side effects without speeding up results.

What if I have no side effects at 0.25 mg? That's common. About 30 to 40% of patients feel little to nothing on 0.25 mg. The therapeutic effect typically starts at 0.5 mg or 1.0 mg. Continue the schedule as labeled.

Can my provider start me at 0.5 mg if I ask? Off-label prescribing is legal, but most providers won't because the side-effect risk doesn't justify the gain. If you've taken semaglutide before and stopped within the past 4 to 8 weeks, your provider may restart you at a higher dose under supervision.

What happens if I accidentally injected 0.5 mg as my first dose? Don't take another dose for 7 days. Hydrate aggressively, eat small bland meals, and contact your provider. Severe nausea, vomiting more than 12 hours, or signs of dehydration (dizziness, dark urine) warrant immediate evaluation.

Is starting at 0.25 mg a waste of a month? No. The 4 weeks at 0.25 mg are setting up the rest of the titration. Patients who try to skip it have a higher dropout rate, which actually delays meaningful weight loss compared to the labeled approach.

Does compounded semaglutide have the same starting dose? Most compounded programs start at 0.25 mg weekly to mirror the FDA label. Some prescribers use 0.125 mg or 0.5 mg based on patient history. Confirm with your provider why you're starting at any specific dose.

Can I split a 0.5 mg dose into two 0.25 mg doses across the week? The standard schedule is one weekly injection. Splitting doses isn't supported by clinical data and changes the pharmacokinetic profile. Some providers allow it during titration for patients with severe side effects, but it's not a self-managed change.

How long until I reach the maintenance dose of 2.4 mg? The labeled schedule is 16 weeks: 4 weeks each at 0.25, 0.5, 1.0, and 1.7 mg before reaching 2.4 mg at week 17. Some patients stay longer at intermediate doses if side effects are persistent.

What's the lowest effective dose of Wegovy? For most patients, 1.0 mg is the lower edge of meaningful weight loss. Some patients respond at 0.5 mg, but the average weight reduction at 0.5 mg in STEP 1 was modest. The maintenance dose is 2.4 mg, with 1.7 mg as a labeled alternative for patients who can't tolerate 2.4 mg.

Can I stay at 0.25 mg long-term? Generally no. The 0.25 mg dose isn't a maintenance dose. It's a stepping stone. Long-term use at 0.25 mg has minimal therapeutic effect and isn't supported by trial data.

Sources

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
2. Novo Nordisk. Wegovy (semaglutide) prescribing information. 2023.
3. Davies M, Faerch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397:971-984.
4. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity (STEP 3). JAMA. 2021;325:1403-1413.
5. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021;325:1414-1425.
6. U.S. Food and Drug Administration. Adverse event reporting system database, semaglutide records. Accessed 2024.
7. Liu W, Hernandez J, Park S, et al. Real-world discontinuation rates among GLP-1 telehealth patients. Obesity Pillars. 2024;9:100096.
8. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: STEP 5 trial. Nat Med. 2022;28:2083-2091.
9. Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of liraglutide for weight management. N Engl J Med. 2015;373:11-22.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.